Congenital disorder of glycosylation
MONDO:0015286Congenital disorder of glycosylation (CDG) is a fast growing group of inborn errors of metabolism characterized by defective activity of enzymes that participate in glycosylation (modification of proteins and other macromolecules by adding and processing of oligosaccharide side chains). CDG is comprised of phenotypically diverse disorders affecting multiple systems including the central nervous system, muscle function, immunity, endocrine system, and coagulation. The numerous entities in this group are subdivided, based on the synthetic pathway affected, into disorder of protein N-glycosylation, disorder of protein O-glycosylation, disorder of multiple glycosylation, and disorder of glycosphingolipid and glycosylphosphatidylinositol anchor glycosylation.
Also known as: CDG, carbohydrate deficient glycoprotein syndrome, carbohydrate-deficient glycoprotein syndrome, congenital disorder of glycosylation, carbohydrate-deficient glycoprotein syndromes, congenital disorders of glycosylation
35 clinical trials for this condition and its sub-types.
Follow this condition to get notified about new trialsSub-types
Broader categories
-
Sugar supplement may calm seizures and stomach troubles in rare genetic disease
Disease control Not yet recruitingThis study tests whether a sugar called D-galactose (AVTX-801) can help people with SLC35A2-CDG, a rare inherited disorder that disrupts how the body adds sugar to proteins. The trial enrolls about 10 people of any age who have seizures or chronic digestive issues. Participants r…
Phase 2 • Sponsor: Eva Morava-Kozicz • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Sugar supplement shows promise for rare disease in new trial
Disease control Not yet recruitingThis phase 2b trial tests AVTX-801, a D-galactose supplement, in 8 adults with PGM1-CDG, a rare genetic disorder affecting sugar metabolism. Participants currently on D-galactose will receive either the study drug or a placebo to see if it reduces disease-related events like low …
Phase 2 • Sponsor: Eva Morava-Kozicz • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for rare anemias: drug may cut transfusions
Disease control Not yet recruitingThis Phase 2 trial tests the drug luspatercept (Reblozyl) in 45 people with rare inherited anemias that affect red blood cells. The goal is to see if it can reduce the need for blood transfusions in those who depend on them, or raise hemoglobin levels in those who don't. Particip…
Phase 2 • Sponsor: EuroBloodNet Association • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Large survey aims to uncover hidden pain in restless legs syndrome
Knowledge-focused Not yet recruitingThis study surveys 1,000 adults with Restless Legs Syndrome (RLS) to find out how often pain is part of their symptoms and how it affects their daily lives. Participants fill out an online questionnaire about their medical history, sleep, pain, and quality of life. The goal is to…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC